![Shachar Shlosberger](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortune : 112 844 $ au 31/05/2026
Shachar Shlosberger is currently the Chief Financial Officer at Enlivex Therapeutics Ltd. She previously worked as the Finance Director at Prolor Biotech Ltd. Shlosberger holds a Master's in Business Administration from The College of Management Academic Studies.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
ENLIVEX LTD. 0,06 % | 18/03/2026 | 139 314 ( 0,06 % ) | 112 844 $ | 31/05/2026 |
| Sociétés | Poste | Début |
|---|---|---|
| ENLIVEX LTD. | Directeur Financier/CFO | 01/01/2016 |
| Sociétés | Poste | Fin |
|---|---|---|
Prolor Biotech Ltd.
 Prolor Biotech Ltd. BiotechnologyHealth Technology Develops proprietary versions of already-approved therapeutic proteins | Directeur Financier/CFO | - |
Actives
Inactives
Sociétés cotées
Entreprise privées
| Entreprise privées | 3 |
|---|---|
The College of Management Academic Studies
 The College of Management Academic Studies Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Prolor Biotech Ltd.
Prolor Biotech Ltd. BiotechnologyHealth Technology Develops proprietary versions of already-approved therapeutic proteins | Health Technology |
Enlivex Therapeutics Ltd.
 Enlivex Therapeutics Ltd. BiotechnologyHealth Technology Develops autologous and allogeneic drug pipeline for treatment of autoimmune and inflammatory conditions | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national
